Clear near vision. Formulation matters.

Discover a solution designed with your early to moderate presbyopic patients’ needs in mind. Qlosi™ offers an alternative that combines proven efficacy, trusted safety, and lasting comfort with a flexible dosing schedule of 1 to 2 doses in each eye per day—an approach unlike any other.

Learn more

Challenge

Patients struggling with Presbyopia will now have a new option

With Qlosi™, your early to moderate presbyopic patients can enjoy a break from their readers, enhanced comfort, and fewer compromises—bringing clarity and ease together.

Presbyopia affects

128 million of adults in America¹

The condition makes everyday tasks like reading a menu or checking a phone screen a constant hassle.

Effective near-vision
correction for your patients

Presbyopia often appears as one of the first signs of aging. Qlosi™ is designed specifically for adults with early to moderate presbyopia who want an effective, discreet, and modern solution.

Presbyopic Emmetrope

For patients frustrated with readers

Adults who don’t need glasses for distance (-0.75 D to +0.50 D) but rely on readers (up to +2.00 D) for near tasks.

Myope

For patients struggling with near-vision tasks

Adults who wear contact lenses and face challenges with close-up tasks and depend on low-power readers (+2.00 D or less).

Low Hyperope

For patients seeking convenient solutions

Adults with mild farsightedness (+0.25 D to +1.25 D) looking for a simple way to manage their near vision changes.

Solution

Clear vision,
on their terms

Explore why Qlosi™ is the reliable near vision enhancement redefining presbyopia care.

Optimized Formulation: Designed for Presbyopes
Proven Efficacy
Tolerability Your Patients Expect
Convenience-Focused Design

Optimized Formulation: Designed for Presbyopes

Lowest effective concentration of pilocarpine, approved for the treatment of presbyopia².
Comfort-enhancing lubricants: HA and HPMC, designed to soothe and protect.
Preservative-free with near-neutral pH for a gentle application.

Proven Efficacy

Nearly 90% of patients taking Qlosi experienced improvement in functional near vision (20/40) or better through Day 15.
Maintaining a consistent pupil diameter of 2-3mm, majority of patients achieved functional near vision for up to 8 hours.

Tolerability Your Patients Expect

Well-tolerated with mild, transient and self-resolving side effects like instillation site discomfort and headaches (5% to 8%).
No impact on mean distance or night vision³.

Convenience-Focused Design

Single-use vials for precise, convenient dosing, empowering your patients to take advantages of flexible dosing.
Compact and ready to use on the go.

Optimized Formulation: Designed for Presbyopes

Lowest effective concentration of pilocarpine, approved for the treatment of presbyopia².
Comfort-enhancing lubricants: HA and HPMC, designed to soothe and protect.
Preservative-free with near-neutral pH for a gentle application.

Proven Efficacy

Proven Efficacy

Nearly 90% of patients taking Qlosi experienced improvement in functional near vision (20/40) or better through Day 15.
Maintaining a consistent pupil diameter of 2-3mm, majority of patients achieved functional near vision for up to 8 hours.

Tolerability Your Patients Expect

Well-tolerated with mild, transient and self-resolving side effects like instillation site discomfort and headaches (5% to 8%).
No impact on mean distance or night vision³.

Convenience-Focused Design

Single-use vials for precise, convenient dosing, empowering your patients to take advantages of flexible dosing.
Compact and ready to use on the go.

Efficacy

Recommend Qlosi™ for clear near vision improvement

Clinical data from Day 8 and Day 15 demonstrates how Qlosi’s formulation delivers efficacy and comfort in a flexible way, ensuring patients can achieve significant near vision improvements with the freedom to take a second dose as needed.

Whether for a busy workday or a special evening out, Qlosi adapts to their lifestyle while minimizing side effects like discomfort or dimming.

Primary endpoint: 40.1% of Patients achieved ≥ 3-line improvement in DCNVA, and no loss of 1-line or more in distance visual acuity (Study Eye) on Day 8 at 1-hour post-dose 1 which was significantly greater (P < 0.0001) than that of the vehicle group (19.1%). Qlosi (n=309) and Vehicle (n=304).

Data from a pooled analysis of two Phase 3, randomized, double-masked, vehicle-controlled clinical studies, NEAR-1 and NEAR-2, Participants (n=613) aged 45 to 64 years old with presbyopia were randomized to either QLOSI n=309 or placebo (n=304) in these two studies and treated for 2 weeks. The primary endpoint of the study was a comparison of the number of participants demonstrating a gain from baseline of 3 lines or more (>= 15 letters) in BDCVA at 40 centimeters without a loss of 1 line or more (>= 5 letters) in BDCVA at 4 meters.

ECP Stories

What your peers are
saying about Qlosi™

Discover why optometrists and ophthalmologists nationwide are excited about Qlosi™ as a breakthrough solution for patients seeking freedom to see close up.

"Our patients live different lives. And it’s really important for us to have an option that fits the flexibility of their lifestyle as well.”

Mark Schaeffer, OD, FAAO

Optometrist

Mark Schaeffer, OD, FAAO

Optometrist

"What is great about Qlosi is that it can give patients another option to help enhance their near vision and reduce their dependency on glasses or other  corrective lenses.”

Gina Wesley, OD, MS, FAAO

Optometrist

Derek Cunningham, OD, FAAO

"We've only been really able to treat presbyopia through prosthetic devices—contact lenses or glasses— or surgery.  Qlosi really presents a brand new aspect  of eye care.”

Clear near vision. Formulation matters.

Challenge

Patients struggling with Presbyopia will now have a new option